All In Biotech

Investigational drug · Phase 3

Volrustomig

Also called: MEDI5752

Not approved by FDA. In 13 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

13

13 still active

All registered trials

20

Any phase or sponsor naming "Volrustomig"

First trial start

2020

Jun 3, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Volrustomig", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Gastric Cancer
  • Non-small Cell Lung Cancer
  • Biliary Tract Cancer
  • Locally Advanced Cervical Cancer
  • Unresectable Pleural Mesothelioma
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Hepatocellular Carcinoma
  • Metastatic Colorectal Cancer
  • Endometrial Cancer
  • Metastatic Castration-resistant Prostate Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Volrustomig" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for Gastric Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • ApatinibRIVO, RivoceranibPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials

    Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • PetosemtamabMCLA-158, GEN1158Phase 35 trials

    Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.